Description of Collaborative Activity: |
There is a major need to integrate clinical pharmacology and disease-specific therapeutic issues—identification of similarities and differences in the etiology, diagnosis, pathophysiology, prognosis, and natural response to therapy—of diseases or conditions affecting children and adults. The National Institute of Child Health and Human Development (NICHD) and the Best Pharmaceuticals for Children Act (BPCA) partly address this need through the IAPT. The Initiative focuses on identifying similarities and differences in diseases or conditions expressed in children and adults by studying etiology, diagnosis, biomarkers, pathophysiology, and outcomes, among other subjects. |
